Reported about 15 hours ago
Novavax's shares surged by 25% after the FDA approved its new protein-based COVID-19 vaccine, Nuvaxovid, designed for older adults and those aged 12 to 64 with underlying health conditions. Developed in partnership with Sanofi, which has agreed to pay Novavax $175 million, the vaccine is distinct from others on the market as it does not use mRNA technology. Commercial delivery is expected in the fall for the 2025-2026 vaccination season.
Source: YAHOO